Just 0.4% of GPs and 0.1% of nursing, midwifery and other health professionals had research as part of their role in 2017.
News
Eyesight leaders urge government to address ‘1:20 funding gap’
Back in October 2019 a WHO World Vision Report found that more than one billion people worldwide are living with sight loss, which is contributed to by a lack of investment in eye care and research.
AZ brings MiNA on board to fight metabolic diseases
The partnership is set to combine MiNA’s “leading expertise” with AstraZeneca’s experience in identifying and bringing breakthrough treatments to patients with metabolic diseases.
Galen takes over POA Pharma, expands reach
Galen first signed a distribution agreement with POA back in April 2016.
Improve brand and batch number recording, urge drug safety professionals
A new study revealed that doctors and nurses only recorded batch numbers for biologic medicines between 38% and 58% of the time.
Keytruda misses key lung cancer survival endpoint
The drug significantly improved progression-free survival, but missed its overall survival endpoint.
Merck’s Bavencio hits targets in bladder cancer interim analysis
Last year the drug disappointed in the Phase III JAVELIN Gastric 100 study, but has pulled itself back with new urothelial carcinoma data.
MSD enlists Otsuka units Taiho and Astex to develop KRAS therapies
KRAS therapies had their break-out moment in 2019, with Amgen’s KRAS inhibitor becoming the first drug of its type to post clinical data last September, demonstrating that it shrank tumors in 90% of lung cancer patients.
AZ scores Priority Review with Farxiga
The US FDA accepted a supplemental New Drug Application for the treatment.
Last year’s finalists share their positive experiences with CROY
Finalists from the 2019 PharmaTimes Clinical Researcher of the Year – The Americas reveal insight into their experience with the competition.
New NHS DNA test could ‘rapidly diagnose’ rare illnesses in babies
“Whole exome sequencing” can double the chance of a diagnosis and reveal what is wrong with patients in days rather than weeks
Incyte JAK1 inhibitor misses the mark in GVHD trial
Despite the setback, the company says that it will continue to study the role of JAK inhibition in chronic GVHD, and in the prophylactic setting.
MHRA updates Dysport license to include upper limb spasticity in children
The treatment is now the first and only botulinum toxin in the UK approved for the treatment of paediatric spasticity in both upper and lower limbs.
Sandoz opens new UK HQ
The new Surrey-based site will be the centre of the company’s UK operations, which encompasses a range of operational functions.
Lynparza bags FDA approval for pancreatic cancer
In a trial the drug nearly doubled the time that patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death
